IDA Foundation, on behalf of the Stop TB Partnership/The Global Drug Facility (GDF), is today launching an Invitation to Bid (ITB) for the supply of ANTI-TUBERCULOSIS MEDICINES AND RELATED PRODUCTS for the treatment of DRUG-RESISTANT FORMS of tuberculosis to eligible manufacturers.
On Monday July 6, Johnson & Johnson announced a price reduction of the anti-tuberculosis medicine bedaquiline, for low- and middle-income countries. Thanks to the support of USAID and the Global Fund, this price reduction could be achieved. The price dropped from $400 to $340 for a six-month treatment regimen.
As the Corona virus pandemic spreads around the globe, and all health care systems and governments seem to be engulfed with battling COVID-19, we realise it is more important than ever that we don’t lose sight of other existing health issues.
While coronavirus (COVID-19) dominates the news, we need to remember that another respiratory disease kills 1.5 million people per year: tuberculosis (TB). This is an opportunity to unite forces in the fight against TB and coronavirus.
As procurement agent for Stop TB /GDF, we are glad to share this news update as announced by the Stop TB partnership during the 50th Union Conference for Lung Health in Hyderabad, India.